Laurus Labs Ltd
NSE:LAURUSLABS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
370.3
589.75
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Laurus Labs Ltd
Laurus Labs Ltd
Net Issuance of Debt
Laurus Labs Ltd
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Laurus Labs Ltd
NSE:LAURUSLABS
|
Net Issuance of Debt
₹6.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Issuance of Debt
₹32.7B
|
CAGR 3-Years
143%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Net Issuance of Debt
-₹5.7B
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Issuance of Debt
₹4.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Issuance of Debt
-₹13.9B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Net Issuance of Debt
₹314.4m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Laurus Labs Ltd
Glance View
Laurus Labs Ltd., an Indian pharmaceutical powerhouse, has etched its presence in the global pharma industry with a focus on delivering affordable and high-quality active pharmaceutical ingredients (APIs). Founded in 2005, the company's trajectory has been nothing short of remarkable, with an emphasis on research-driven production and sustainability. The Hyderabad-based conglomerate cultivates its core expertise within key therapeutic areas such as antiviral, cardiovascular, and oncology medications. By amalgamating scientific prowess with cutting-edge manufacturing facilities, Laurus Labs has positioned itself as a fundamental supplier in the fight against global ailments, providing APIs to some of the most critical generic pharmaceuticals worldwide. The company's commitment to health innovation is reflected in its robust portfolio of over 60 commercialized APIs, substantiating its pivotal role in the pharmaceutical supply chain. Adding another feather to its cap, Laurus Labs has ventured into the formulation business, manufacturing finished dosage forms that reach consumers directly. This vertical integration allows Laurus to capture a larger share of the pharmaceutical value chain, maximizing returns from its research and manufacturing capabilities. The company's foray into generic formulations has opened doors to new markets, particularly in challenging economies where cost-effective treatment is crucial. By leveraging its API expertise to produce effective, high-quality generic medications, Laurus Labs not only enhances its profitability but also adheres to its founding ethos of making healthcare accessible. With investments in research and development and a commitment to expanding its product line, Laurus Labs continues to strengthen its presence while nurturing partnerships globally, fueling its growth trajectory.
See Also
What is Laurus Labs Ltd's Net Issuance of Debt?
Net Issuance of Debt
6.2B
INR
Based on the financial report for Sep 30, 2024, Laurus Labs Ltd's Net Issuance of Debt amounts to 6.2B INR.
What is Laurus Labs Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 3Y
-1%
Over the last year, the Net Issuance of Debt growth was 1 475%. The average annual Net Issuance of Debt growth rates for Laurus Labs Ltd have been -1% over the past three years .
You don't have any saved screeners yet
